EARLY-STAGE IVD CONSULTING FAQS

Feasibility, troubleshooting and development strategy - common questions answered.

Technical answers for diagnostics founders, R&D teams, investors and academic translation teams working at the point where strong science must become a credible development proposition.

  • The highest-impact timing for independent advisory input is before feasibility is assumed rather than proven - specifically before investor discussions, grant applications or major development investment. Other critical points include when assay performance is inconsistent and root cause is unclear; when preparing for development transfer, scale-up or CDMO engagement; and when an investor or partner requires independent technical assessment. Engaging earlier reduces the cost of changes and avoids development decisions made on incomplete or misinterpreted evidence.

  • The highest value is created at four specific moments: before investor discussions or grant applications (to build a defensible technical story); before capital is committed to development (to identify hidden debt); three to six months before CDMO transfer or scale-up (to assess transfer readiness and prevent failures); and when assay performance issues are stalling progress (to identify root cause and restore momentum). At each point, the cost of independent input is low relative to the cost of proceeding without it.

  • External expertise is most valuable when data is unclear, inconsistent or difficult to interpret in the context of a development or investment decision. Independent input removes the internal pressure to validate existing assumptions and brings structured evaluation of what the evidence actually supports. This is particularly important before major resource commitments - development, funding discussions or partnership negotiations, where technically optimistic interpretation of early data can create significant downstream risk.

  • Independent technical assessment reduces development risk by identifying hidden risks in assay architecture, reagent strategy and performance claims before they become expensive development problems. A structured review surfaces what the evidence actually supports, what is still uncertain and what must be addressed before the next development step. This creates clearer go, refine or pause decisions and reduces the probability of late-stage failures, which are consistently more costly than early-stage corrections.

When & Why to Engage a Consultant

  • Yes. ORIVISE applies structured root-cause analysis to identify the underlying drivers of variability, instability or poor performance, distinguishing between assay architecture problems, reagent issues, bioconjugation failures and process variables. The output is a structured problem map, a prioritised set of hypotheses and a focused experimental plan that reduces costly iteration by targeting the most likely cause rather than testing everything sequentially.

  • Immunoassay variability is usually driven by underlying system instability rather than a single controllable parameter. The most common root causes are inconsistent bioconjugation, where antibody-particle or label attachment degrades between preparations or batches. Reagent instability affect binding characteristics over time, and poorly controlled assay conditions including buffer composition, temperature, incubation timing and operator technique. Identifying which factor is dominant requires structured root-cause analysis, not iterative optimisation across all variables simultaneously.

  • High background signal in immunoassays is typically caused by non-specific interactions: inadequate blocking of the assay surface, non-specific antibody binding to matrix components, or suboptimal assay architecture that creates detectable signal in the absence of the target analyte. In particle-based systems, aggregation of the labelled reagent can also contribute significantly to elevated background. Addressing blocking strategy, antibody concentrations, wash conditions and surface chemistry is usually the first step in diagnosis.

  • Common bioconjugation issues include inconsistent coupling efficiency between batches, loss of antibody or protein biological activity during the conjugation process, aggregation of the conjugated particle or label, and instability of the conjugate under storage or assay conditions. These problems directly impact assay sensitivity, specificity and lot-to-lot reproducibility. They are frequently missed at early feasibility stage because single-batch performance appears acceptable, with failures only becoming visible when multiple batches or lots are compared.

  • Reproducibility improves by systematically identifying and controlling the variables that drive assay behaviour — this requires characterising which parameters have the greatest influence on performance, then standardising their control. Key areas include reagent stability and lot-to-lot consistency, assay conditions (buffer composition, pH, temperature, timing), conjugation process robustness and operator technique. Reproducibility problems that persist despite optimisation often indicate a fundamental instability in the assay architecture or reagent strategy that requires structural rather than incremental intervention.

Assay challenges and troubleshooting

  • Before scale-up, the assay must demonstrate consistent performance across defined conditions, with clearly defined critical parameters and evidence that lot-to-lot reagent variability is controlled. Reagent stability, reproducibility under manufacturing conditions and process robustness are essential prerequisites. Unresolved variability at small scale will amplify at manufacturing scale, and assumptions that performance will translate — without evidence — are a common source of costly transfer failures.

  • Transfer failures typically occur when variability or instability present at small scale has not been fully characterised and addressed before transfer. Critical assay parameters are often not formally defined, so small changes in reagent lots, environmental conditions or operator technique at the receiving site create unexpected performance shifts. Transfer also exposes assumptions about reagent scalability, formulation stability and operator independence that were never tested during early development — and were not visible in the data presented at the transfer decision point.

  • An assay is development-ready when it demonstrates stable, reproducible performance across defined conditions and operators; has clearly defined critical assay parameters; shows that performance is consistently achievable across multiple independent runs — not demonstrated once under optimised conditions; and has a reagent strategy and evidence base mature enough to support a clear, costed development plan. Development readiness is not a single threshold — it is assessed relative to the specific next decision: transfer, investment, partnering or regulated development.

Development & Scale-Up Readiness

  • ORIVISE provides independent technical evaluation and decision support — not laboratory execution. Where CROs generate data, ORIVISE focuses on ensuring the right questions are being asked of existing data and that development decisions are based on robust technical foundations before resources are committed. ORIVISE is complementary to CROs: independent advisory input defines what experiments are needed and why, what evidence would satisfy the decision, and what risks exist in the current data — while laboratory partners execute the work.

  • No. ORIVISE provides independent advisory support and technical decision-making input rather than laboratory execution. This ensures all recommendations remain unbiased and focused on what is technically and commercially viable — rather than what generates further laboratory work. Where laboratory experiments are required as a result of the advisory review, ORIVISE can provide experimental direction and help identify appropriate laboratory partners to execute that work.

  • Outputs vary by service type but typically include one or more of: a technical risk and feasibility summary with evidence-gap analysis; a development-readiness assessment with prioritised actions; a structured troubleshooting plan with root-cause hypotheses; a technical due diligence memo with red-flag findings and investor questions; or a grant-led translation narrative with stronger technical work packages. All outputs are framed around the specific decision — go, refine, pause or investigate further — that the engagement was scoped to support.

  • ORIVISE primarily supports immunoassays — including ELISA, lateral flow, particle-based and bead-based systems — with particular depth in assay architecture, reagent strategy, bioconjugation and analytical performance. The advisory framework is also relevant across a broader range of diagnostic platforms including point-of-care, biosensor-based and molecular diagnostic systems where early feasibility, technical risk and development readiness need independent evaluation.

  • ORIVISE provides independent technical due diligence for investors evaluating early-stage diagnostic opportunities — assessing assay design, data quality, technical claims and underlying development risks to determine whether the scientific evidence supports the investment case. Output is a technical due diligence memo that identifies red flags, unsupported claims, missing evidence and the prioritised questions that investors should raise with founders before making a funding decision.

  • Yes. ORIVISE can review technical data room materials to identify red flags, unsupported claims, missing evidence and questions that investors should raise before committing capital. This includes assessment of assay performance claims, evidence quality, development assumptions, reagent and reproducibility risks, and the technical credibility of the development plan and timeline presented in the data room.

  • Yes. ORIVISE can provide technical and commercialisation input for grant-led diagnostic translation — including feasibility planning, evidence-gap analysis, risk framing, development-readiness review and strengthening the technical work packages that underpin grant applications. Independent technical input increases the credibility of the feasibility rationale and development plan for funders, TTOs and translation programmes evaluating early-stage diagnostic science.

How ORIVISE Works

  • An early-stage IVD consultant evaluates whether an assay is technically viable, identifies key risks in the assay architecture, reagent strategy and development assumptions, and provides clear go, refine or stop recommendations before full development begins. The focus is on decision support, ensuring that data is interpreted against the right question and that resources are not committed before the evidence supports progression. This is distinct from laboratory execution, which CROs and CDMOs provide.

  • Assay feasibility is the systematic assessment of whether an in vitro diagnostic assay can realistically achieve required analytical performance including sensitivity, specificity and reproducibility under practical development conditions. It matters because most IVD programmes that stall or fail do so not because the science lacks promise, but because feasibility assumptions were never tested against a clear decision framework. Addressing feasibility properly at the outset prevents expensive rework during development and reduces the risk of failed investment or transfer decisions.

  • Feasibility assessment involves evaluating the detection mechanism, reagent and bioconjugation strategy, expected sensitivity and specificity in the intended sample matrix, and potential sources of variability, all in the context of the specific development or investment decision the data must support. A structured approach uses defined evidence categories (what is supported, what is partly supported, what is unsupported and what has not yet been assessed) rather than binary pass/fail judgements, which rarely reflect the complexity of early assay data.

  • Before entering structured IVD development, you should have preliminary evidence of sensitivity and specificity in a relevant sample matrix, initial reproducibility data across multiple runs, a defined assay architecture and reagent strategy, and clarity on the key variables that influence assay behaviour. You also need a stated intended use and a target product profile defining the performance standards the assay must meet. Without these, development investment is at high risk of generating data that cannot support the next decision.

  • Technical debt in diagnostics arises when assay data is generated without a clear decision framework: accumulating unresolved questions, untested assumptions and characterisation gaps that appear manageable early but compound during scale-up, CDMO transfer or regulatory review. It manifests as unexpected variability, failed transfer, the need to repeat characterisation studies or inability to demonstrate reproducibility in a regulated environment. Identifying and addressing technical debt during feasibility is far less costly than resolving it during or after development.

Understanding early-stage IVD development

Still have a question?

Share a brief outline of your project and ORIVISE will confirm whether it is in scope and what the right next step is.

Book a discovery call →